SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-458778"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-458778" > A Population Pharma...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005316naa a2200457 4500
001oai:DiVA.org:uu-458778
003SwePub
008211221s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4587782 URI
0247 a https://doi.org/10.1097/FTD.00000000000008772 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Elkayal, Omaru Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.4 aut
2451 0a A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients :b A Short Communication
264 1b Wolters Kluwer,c 2021
338 a print2 rdacarrier
520 a Background: Posaconazole oral suspension emerged as a promising candidate for prophylaxis of invasive fungal infections in immunocompromised children. Its pharmacodynamic advantages include a broad-spectrum activity and a favorable safety profile; however, they are overshadowed by its large pharmacokinetic (PK) variability, which might cause subtherapeutic exposure. The aim of this study was to develop a population (pop) PK model based on rich sampling data to better understand the PK of posaconazole oral suspension in pediatric patients. Methods: Data were obtained from a prospective interventional study involving hospitalized pediatric patients with a hematologic malignancy and prophylactically treated with posaconazole oral suspension. After constructing the popPK model, the probability of target attainment (PTA; 100% T >= 0.7 mg/L) for prophylaxis under fixed, body weight-based, and body surface area-based dosing was evaluated using Monte Carlo simulation. Results: Fourteen patients contributed 112 posaconazole plasma concentrations. The PK of posaconazole was adequately described by a 1-compartment model with lag time 2.71 hours [13%]; nonlinear bioavailability ED50 99.1 mg/m(2) (fixed); first-order absorption rate constant 0.325 hour(-1) [27%]; apparent volume of distribution 1150 L [34%]; and apparent clearance 15.4 L/h [24%] (similar to 70-kg individual). The bioavailability decreased in the presence of diarrhea and co-treatment with a proton pump inhibitor (PPI). The unexplained interindividual variability in posaconazole PK remained large. The PTA was <85%, irrespective of the simulated dosing strategy. Patients without diarrhea and not administered a PPI had the highest PTA (85% under the fixed 300-mg dosing 4 times per day). Conclusions: Therapeutic drug monitoring is recommended during prophylactic posaconazole therapy in immunocompromised pediatric patients. Large-scale comparative studies are needed to characterize the PK variability between different posaconazole formulations in this cohort.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng
653 a posaconazole
653 a pediatrics
653 a therapeutic drug monitoring
653 a population pharmacokinetics
653 a oral suspension
653 a Pharmacology
653 a Farmakologi
7001 a Spriet, Isabelu Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.;Univ Hosp Leuven, Pharm Dept, Leuven, Belgium.4 aut
7001 a Uyttebroeck, Anneu Katholieke Univ Leuven, Paediat Oncol Unit, Dept Oncol, Leuven, Belgium.;Univ Hosp Leuven, Pediat Oncol & Hematol Dept, Leuven, Belgium.4 aut
7001 a Colita, Ancau Fundeni Clin Inst, Dept Pediat, Bucharest, Romania.;Carol Davila Univ Med & Pharm, Dept Pediat, Bucharest, Romania.4 aut
7001 a Annaert, Pieteru Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.4 aut
7001 a Allegaert, Karelu Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.;Katholieke Univ Leuven, Woman & Child Unit, Dept Dev & Regenerat, Leuven, Belgium.4 aut
7001 a Smits, Anneu Katholieke Univ Leuven, Woman & Child Unit, Dept Dev & Regenerat, Leuven, Belgium.;Univ Hosp Leuven, Neonatal Intens Care Unit, Leuven, Belgium.4 aut
7001 a Van Daele, Ruthu Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.;Univ Hosp Leuven, Pharm Dept, Leuven, Belgium.4 aut
7001 a Dreesen, Erwinu Uppsala universitet,Institutionen för farmaci4 aut0 (Swepub:uu)erwdr842
7102 a Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.b Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Clin Pharmacol & Pharmacotherapy Unit, Leuven, Belgium.;Univ Hosp Leuven, Pharm Dept, Leuven, Belgium.4 org
7730 t Therapeutic Drug Monitoringd : Wolters Kluwerg 43:4, s. 512-518q 43:4<512-518x 0163-4356x 1536-3694
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-458778
8564 8u https://doi.org/10.1097/FTD.0000000000000877

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy